Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at ASH
SAN DIEGO, Dec. 05, 2020 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medi…
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
December 05, 2020 - SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), today announced four-year follow-up data from the pivotal ZUMA-1 tri…
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: ASH Update
BOSTON, MA, December 5, 2020 - Verastem, Inc. (Nasdaq:VSTM), a biopharmaceutical company today presented the expansion phase initial results for COPIK…
Affimed Announces Publication of Final Study Results of AFM13 in Combination with anti-PD-1 therapy in Blood
Heidelberg, Germany, November 19, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their…
Promising Preclinical Combinations of AFM13 and Natural Killer Cells Presented at SITC
Heidelberg, Germany, November 9, 2020 - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their …
News
LLS Statement on Oral Arguments in California v. Texas
This week, the Supreme Court of the United States hears oral arguments in California v. Texas, the case challenging the Affordable Care Act.
Sanofi offers to acquire Kiadis for €308 million
Paris, France and Amsterdam, The Netherlands, 2 November 2020 – Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf' NK-cells from a…
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia
GAITHERSBURG, MD - October 27, 2020 - NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunother…
Research
HCL2025 guidelines
The HCLF and LLS joining forces to expanding research in Hairy Cell Leukemia to better characterize its biology, develop new therapies, and optimize o…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
